[Benefits and risks of antiplatelet therapy. A retrospective study].
Seven hundred and forty-six patients with cerebral infarction (except those with cardiogenic embolism) were retrospectively studied to determine the effect of antiplatelet agents on the prevention of recurrence and the incidence of cerebral hemorrhage, as an adverse effect of the drugs. The average follow-up period was 26.5 months for the fatal cases and 41.3 months for the survivors. Cerebral infarction recurred in 41 patients (3.1%/year) during the period of administration of antiplatelet agents, while it occurred in 66 (5.4%/year) untreated patients (p less than 0.01). Cerebral hemorrhage occurred 14 times in 14 patients; 7 (0.5%/year) during the antiplatelet treatment and 7 (0.6%/year) during the period without antiplatelet agents. No evidence was found that cerebral hemorrhage was promoted by antiplatelet agents.
Nishimaru
K
K
Department of Internal Medicine, School of Medicine, Fukuoka University.
Yamaguchi
T
T
D002543:Cerebral Hemorrhage / Q000139:chemically induced; D002544:Cerebral Infarction / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies; D012306:Risk
D010975:Platelet Aggregation Inhibitors